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The knowledge on the genetic etiology of complex disorders largely results from the study of rare monogenic disorders. Often these
common and rare diseases show phenotypic overlap, though monogenic diseases generally have a more extreme symptomatology.
ABCC6, the gene responsible for pseudoxanthoma elasticum, an autosomal recessive ectopic mineralization disorder, can be
considered a paradigm gene with relevance that reaches far beyond this enigmatic orphan disease. Indeed, common traits such as
chronic kidney disease or cardiovascular disorders have been linked to theABCC6 gene.While during the last decade the awareness
of the wide ramifications of ABCC6 has increased significantly, the gene itself and the transmembrane transporter it encodes have
not unveiled all of the mysteries that surround them. To gain more insights, multiple approaches are being used including next-
generation sequencing, computational methods, and various “omics” technologies. Much effort is made to place the vast amount
of data that is gathered in an integrated system-biological network; the involvement of ABCC6 in common disorders provides a
good view on the wide implications and potential of such a network. In this review, we summarize the network approaches used to
study ABCC6 and the role of this gene in several complex diseases.
1. Introduction
In the western world, the most frequent health problems
occur due to complex disorders, such as diabetes, obesity,
cancer, and cardiovascular disease [1]. The traditional para-
digm for the etiology of these common diseases includes a
role for (common) genetic variants, which interact with envi-
ronmental risk factors, together often coined as a multi-
factorial etiology [2]. However, dissecting the genes and
mechanisms involved in complex diseases has only yielded
limited successes, with several reasons for these shortcom-
ings. First, many variants increase the susceptibility to a
disease but their individual risk is often too low to be detected
by currently used methods. Second, the genetic variants
usually require environmental triggers, which need to be
taken into account in the search for the underlying genetic
causes. As a consequence of these hurdles, the study of rare
monogenic disorders, for many of which the genetic causes
have been successfully identified in the past, is often said
to be a good prerequisite for the understanding of complex
disorders since they may show phenotypic overlap with
common health problems [3]. However, given the generally
more extreme phenotypes of these monogenic disorders,
they seem to be easier to study, since they often represent a
model of dysfunction of a single biological pathway. Besides
pathophysiological insights, knowledge, translated from a
rare disease to a more common health problem, can also
include innovative targets or options for treatment.
In this review, we exemplify the added value of studying a
rare disease, that is, the ectopic mineralization disorder pseu-
doxanthoma elasticum (PXE, OMIM#264800), and more
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Figure 1: ABCC6 topology model. ABCC6 is a transmembrane transporter, consisting of 3 transmembrane domains (TMD0–2) and 2 linker
regions: the latter are built up by the 2 ABCmotifs with the 2 nucleotide-binding folds (NBF1-2). Furthermore, there are 2 glycosylation sites
in the extracellular part of the transporter.
specifically its causal gene ABCC6, for a wide range of more
common health as stated in the following list:
(1) Renal disease:
(i) chronic kidney disease,
(ii) nephrocalcinosis.
(2) Cardiovascular disease:
(i) coronary heart disease,
(ii) cardiomyopathy,
(iii) dyslipidemia.
(3) Ophthalmological disease:
(i) age-related macular degeneration.
(4) Cerebral disease:
(i) ischemic stroke.
(5) Hematological disease:
(i) beta-thalassemia.
The use and integration of different research tools (compu-
tational, molecular, and biological) in patients, animal, and
in silicomodels are emphasized. It is highlighted that proteins
which are best known for their association with a rare genetic
disorder can have much wider ramifications and that study-
ing them not only benefits patients suffering from rare dis-
orders but also extends the insights in the genetic factors, cell
signaling, and (future) therapies in commonhealth problems,
hence improving the welfare of a much larger patient popu-
lation.
2. ABCC6
The ABCC6 (adenosine triphosphate-binding cassette, sub-
family C, member 6; OMIM#603234) transporter, also
known as MRP6 (Multidrug Resistance Protein 6), is a trans-
membrane transporter belonging to the superfamily of 49
ABC transporters (Figure 1) [4, 5]. Though it is long known
that ABCC6 is primarily expressed in the liver and kidney,
to date, the substrate(s) of this transporter remain to be
elucidated [6]. Despite marked structural resemblance with
other ABC transporters, ABCC6 is considered the odd one
out as mutations in the ABCC6 gene, by which it is encoded,
cause PXE, an autosomal recessive connective tissue disease
primarily characterized by mineralization and fragmentation
of elastic fibers (EFs) in the extracellular matrix (ECM) [4, 7,
8]. Surprisingly, ectopic calcification primarily occurs in soft
tissues with minimal expression of the ABCC6 transporter,
suggesting that it has a pivotal metabolic role [4, 8]. While
ABCC6 is abundantly present in the liver and kidney, PXE
patients present a complex phenotype (highly variable in
clinical severity) consisting of skin, eye, and cardiovascu-
lar symptoms [9, 10]. The skin develops papular lesions,
increased skin laxity, and skin folds, mainly in the flexural
areas of the body. Ophthalmological manifestations are due
to EF fragmentation in Bruch’s membrane, a layer which
is localized in between the retinal pigment epithelium and
the choroidal capillaries, causing a retinopathy characterized
by choroidal neovascularization, hemorrhage, and vision
loss [11, 12]. The cardiovascular symptoms mainly consist of
peripheral and coronary artery disease, which resemble but
are not identical to atherosclerosis [13]. As such, the PXE
phenotype shows considerable overlap with the symptoms
of the common disorders listed in Section 1. More recently,
ABCC6 mutations were also shown to cause generalized
arterial calcification of infancy (GACI, OMIM# 208000),
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Figure 2: Putative biological pathways related to ABCC6. ABCC6 is mainly expressed in the liver (and the kidneys) and has currently
unknown substrates. Furthermore, the molecular mechanisms underlying PXE are still widely unknown but are traditionally explained by
the metabolic hypothesis, focusing on the hepatic localization of ABCC6, and the cellular hypothesis, focusing on the role of fibroblasts
and peripheral cells. Both are however not necessarily mutually exclusive as shown in this scheme. In the liver, it was shown that ATP is
secreted via an ABCC6-dependent mechanism (although ABCC6 itself does not transport ATP). ABCC6 deficiency leads to a hampered
transport function, causing a strongly reduced PPi level, which normally inhibits hydroxyapatite growth and hereby mineralization [24].
Further, in PXE, a lower vitamin K (VK) concentration is seen. VK is an essential cofactor of 𝛾-carboxylation, which is necessary to activate
antimineralizing proteins, such as OC and MGP. Ineffective activation of MGP and OC in peripheral cells also leads to a tissue-specific
loss of inhibition of ectopic mineralization together with the diminished levels of the systemic calcification inhibitor fetuin-A [25–27].
Next to these findings, an upregulation of 3 proosteogenic pathways, that is, MSX2-WNT, BMP2-RUNX2, and TGF𝛽-CTGF, was found
in all PXE-affected tissues compared to controls, which further enhance the ectopic mineralization. These pathways are also associated
with altered MMP9 and caspase regulation, leading to apoptosis, and altered VEGF regulation, inducing neovascularization [15]. ABCC6:
adenosine triphosphate-binding cassette, subfamily C, member 6; AMP: adenosine monophosphate; ATP: adenosine triphosphate; BMP2:
bone morphogenetic protein 2; C: carboxyl; ENPP1: ectonucleotide pyrophosphatase/phosphodiesterase 1; GGCX: 𝛾-glutamyl carboxylase;
MGP: matrix Gla protein; MMP9: matrix metalloproteinase; MSX2: muscle segment homeobox, Drosophila, homolog of, 2; NT5E: ecto-5-
prime nucleotidase or CD73; OC: osteocalcin; Pi: inorganic phosphate; PPi: inorganic pyrophosphate; RUNX2: runt-related transcription
factor; Smad: mothers against decapentaplegic, Drosophila, homolog of; TGF𝛽: transforming growth factor 𝛽; TNAP: tissue-nonspecific
alkaline phosphatase; VEGF: vascular endothelial growth factor; WNT: wingless-type MMTV integration site family.
featuring extensive vascular calcification and vessel fibrosis
in childhood [14].
Despite the disadvantage of not knowing the substrates,
important progress has been made in the unraveling of the
mechanisms in which ABCC6 is involved (Figure 2). To this
end, a combination of several approaches is being used,
including next-generation sequencing, computational meth-
ods, and various “omics” technologies. In doing so, ABCC6
was found to play a role inmore pathophysiological processes
than could initially be envisaged based on its association
with PXE. From this perspective, the ABCC6 transporter is
becoming increasingly important for a growing number of
diseases (Figure 3).
3. A Network Approach towards a Better
Understanding of the ABCC6 Transporter
Over the past years, the field of genetics and genomics has
experienced a revolution in the way we think about bio-
logical mechanisms and cellular signaling, which for an
important part is due to remarkable technological advances.
Increasingly, scientific exploration of diseases uses a diverse
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Figure 3: Reviewof the disorders andpathophysiologicalmechanisms associatedwith theABCC6 transporter, which is primarily expressed in
the liver and kidney. Chronic deficiency of the transporter is involved in rare disorders such as pseudoxanthoma elasticum (PXE), generalized
arterial calcification of infancy (GACI), and PXE phenocopies in thalassemias. More acute ABCC6 deficiency is a susceptibility factor and/or
amodifier for stroke, myocardial infarction (MI), cardiac fibrosis, peripheral artery disease (PAD), age-relatedmacular degeneration (AMD),
chronic kidney disease (CKD), nephrocalcinosis, and dyslipidemia. BMP2: bone morphogenetic protein 2; MGP: matrix Gla protein; MSX2:
muscle segment homeobox 2; OC: osteocalcin; PPi: inorganic pyrophosphate; TGF: transforming growth factor [4, 7–9, 12, 14, 28–45].
repertory of approaches to gain insights into the biology
underlying a specific disease or protein. These approaches
include next-generation sequencing, expression assays, pro-
teomics, transcriptomics, metabolomics, network analysis,
and computational biology. Besides the challenges of inter-
preting the large datasets that are gathered by some of these
high-throughput technologies, the integration of all this
knowledge into a unified system-biological structure is par-
ticularly challenging (Figure 4).
ABCC6 is a prime example on how different approaches,
each with its own benefits and particularities, are being used
to further unravel this enigmatic protein. However, consider-
ing that the substrate(s) of the transporter remain unknown
despite more than 15 years of research, the focus has shifted
from the protein itself to the potential downstream effects
of ABCC6 deficiency [15], which may give valuable clues to
its function. In the following paragraphs the most commonly
used model systems and techniques in ABCC6 research will
be discussed.
3.1. Molecular Analysis Tools. The gold standard for mole-
cular analysis of ABCC6 is Sanger sequencing, which can be
complemented with a Multiplex Ligand Probe Amplification
(MLPA) assay to detect deletions and duplications that would
be missed with conventional sequencing [16, 17]. Depending
on the cohort, mutation detection rates vary from 70 to 90%,
with most mutations located in the 3󸀠 coding region of
the gene [16, 17]. A public database enlisting the reported
mutations is available at the Leiden Open Variation Data-
base (LVOD, http://www.ncbi.nlm.nih.gov/lovd/home.php?
select db=ABCC6), while neutral variants can be found in
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/).
More recently, next-generation sequencing (NGS) has
been evaluated as a diagnostic strategy for detecting
mutations in ABCC6 and related genes such as ecto-
nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1,
OMIM∗173335) and gamma-glutamyl carboxylase (GGCX,
OMIM∗137167) [18]. Targeted analysis of whole exome
sequencing data yielded a mutation detection rate compa-
rable with that of Sanger sequencing with an overall coverage
of 37 and over 90% coverage of all ABCC6 exons. Annotation
of variants was done with in-house developed software which
uses Ensembl API and Alamut Batch, while filtering of rele-
vant variants was done using in silico tools as specified below.
To detect false positives, all variants were confirmed with
Sanger sequencing. Besides the absence of false positives, it
was interesting that also intragenic deletions, considered one
of the pitfalls of NGS, could be detected with this approach,
possibly making MLPA redundant in the future.
More than 60% of the reported ABCC6 mutations are
missense variants; until now, causality of these variants has
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Figure 4: Schematic representation of themultistep process starting from a rareMendelian disease such as PXE and subsequent identification
of the causal gene(s). From then, a combination of technological approaches is performed in severalmodel systems to gain insights into cellular
signaling. This knowledge can already be of relevance for common disorders, which show an overlap with the phenotype of the rare disease,
but can also be used for development of innovative treatments, which benefit patients of both orphan and complex disorders [20, 21, 46–54].
been assumed based on their absence in SNP databases and
large exome or genome datasets, the conservation of the
affected nucleotide and amino acid, the presumed changes
in physicochemical properties, and in silico prediction tools
such as SIFT, PolyPhen, and MutationTaster (Table 1) [16]. It
is however well known that the predictions of which variants
are deleterious or tolerated made by the latter are often not
congruent with reality and should ideally be confirmed with
in vitro or in vivo functional studies. So far, only limited
functional data are available proving causality of missense
variants. In 2002, Ilia´s et al. used an in vitromodeling system
in Sf9 (Spodoptera frugiperda) insect cells to establish that 3
ABCC6missensemutations lead to a loss of transport activity
(supplemental Table 1 in Supplementary Material available
online at http://dx.doi.org/10.1155/2015/648569) [19]. Since
then, consequences of missense mutations have also been
tested in vivo in a C57BL/6J mouse model, that is, a substrain
of the C57BL/6 or “black 6” mouse model, which examined
the subcellular localization of the mutant protein in the liver
[20, 21]. It has been demonstrated that some missense muta-
tions lead to retainment of the protein in the cytoplasm,
whilst others allow the protein to target its physiological
location in the plasma membrane (supplemental Table 1).
The former could in some cases be rescued using 4-phenyl-
butyrate which is known to restore intracellular trafficking.
More recently, an additional 7 missense mutations were
proven to be causal using rescue experiments in an abcc6a
morpholino-based zebrafish model (supplemental Table 1)
[22]. The phenotype of the morphant could not be rescued
with coinjected human ABCC6mRNA carrying one of these
variants, thus demonstrating their deleterious effect.
With the advent of the CRISPR-Cas9 technology as a
novel paradigm for genome editing, it can be anticipated
that additional functional data of knownmissense mutations
and variants of unknown significance will become available.
This ground-breaking technology delivers the Cas9 protein,
a nuclease that has the potential to cleave DNA together with
specific guide RNAs to the cell and can cut the genome at
the desired location [23]. Besides an accurate idea on the
actual mutation detection rate, the emerging possibilities of
mutation-specific therapies, such as 4-phenylbutyrate, will
increase the need for reliable functional data [21].
3.2. In Vivo Models (Animal Models). Animal models are
used in fundamental research, because of the ethical dilem-
mas often associated with the use of human tissues for
research that does not have immediate therapeutic conse-
quences. Specifically for ABCC6, the paucity of patient tissue
due to difficulties with prelevation (e.g., for the liver or eye)
also presents an important hurdle. Because of significant gene
conservation (depending on the species) between humans
and the frequently used mice and more recently zebrafish
(ZF) models, animal models can be a valid alternative for
these human tissues.
3.2.1. Mice (Mus musculus). In mice the Abcc6 protein is also
predominantly expressed in liver and kidney, though renal
Abcc6 is considerably lower compared to humans [28, 55,
56]. Thus far, 2 Abcc6 KO mouse models have been created,
one through deletion of the nucleotide-binding fold (NBF1)
coding region (Figure 1), a hotspot forABCC6mutations, and
a secondmodel via targeted ablation of introns 14–18 [28, 57].
Both models show phenotypic overlap, with spontaneous
calcification of EFs (mainly in arteries, the renal cortex, and
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Table 1: In silico prediction tools used to study causality of ABCC6 missense variants.
Bioinformatics tool Web address
Annotation of variants
Ensembl API http://rest.ensembl.org/
Alamut Batch http://www.interactive-biosoftware.com/alamut-batch/
Functional consequences of mutations
Alamut http://www.interactive-biosoftware.com/software/alamut/overview
Polyphen 2 http://genetics.bwh.harvard.edu/pph2/
SIFTs https://www.ebi.ac.uk/pdbe/docs/sifts/
Align-GVGD http://agvgd.iarc.fr/agvgd input.php
MutationTaster http://www.mutationtaster.org/
SpliceCenter http://projects.insilico.us/SpliceCenter/SpliceOverview.jsp
MutationAssessor http://mutationassessor.org/v1
Structural consequences of mutations
PredictProtein https://www.predictprotein.org/
MutDB http://www.mutdb.org
Large sequencing datasets
1000 genomes browser http://www.1000genomes.org/
Exome variant server http://evs.gs.washington.edu/EVS/
the capsule surrounding the sinuses of the vibrissae) and nor-
mal plasma mineral levels [28, 57]. The prominent vibrissae
calcification has been suggested to be a useful biomarker for
the phenotype of these mice, though there is no consensus
about its relevance for PXE patients [57, 58]. Distinct features
of the targeted ablation model include mineralization of
dermal EFs and collagen, lower plasma HDL cholesterol, and
increased plasma creatinine [28, 57].
A third mouse model that mimics the Abcc6−/− pheno-
type is the dystrophic cardiac calcification (DCC) or Dyscalc
mousemodel [29, 59].Thismodel harbors anAbcc6missense
mutation, causing truncation of the protein via the presence
of an additional donor splice site. Distinct features are the
presence of myocardial calcification and the absence of vas-
cular and vibrissa calcification [29, 60]. Putative explanations
for these features are a residual Abcc6 activity in these mice
and/or their different genetic backgrounds [29]. Sowa et al.
studied the expression of osteogenic factors in the Dyscalc
mice and found an upregulation of Runx2 in these mice
compared to control mice [61]. This is concordant with the
findings of Hosen et al. in the Abcc6−/− mouse and confirms
the added value and complementary character of this murine
model [15].
Recently, 4 inbred strains were identified with a sponta-
neous, nonsynonymous SNP with interference of the Abcc6
splicing in the liver, which is the primary expression site of
murine Abcc6. These models, that is, KK/HIJ, 129SI/Svlmj,
C
3
H/HeJ, and DBA/2J, show highly variable mineralization
phenotypes, rendering them interesting for studying ectopic
mineralization (Table 2) [60, 62–64].
Despite the expression profile and the phenotypic resem-
blance, murine models also present limitations such as
their relatively long development time and expensive and
labor-intensive maintenance, laborious genome editing and,
specifically for PXE, a relatively slow onset of the disease [65].
For these reasons, alternative model systems were strived for.
3.2.2. Zebrafish (Danio rerio). The ZF was introduced as a
novel animal model for ABCC6 research, because of several
important advantages compared to mouse models. These
include its small size, relative low cost and its fecundity
(approximately 100 embryos/week can be generated by 1 ZF
pair), its rapid development, and the transparency of the
embryos and early adults, which makes it easier to study
the internal organs, using light microscopy [65–67]. Because
of high conservation of key regulators for skeletal develop-
ment and calcium metabolism compared to mammals, with
significant sequence similarities and overlap in expression
between orthologues, ZF are considered a goodmodel system
to study mineralization. A potential disadvantage of ZF,
specifically for the ABCC6 research, is the presence of 3
abcc6-related sequences: abcc6a, abcc6b, and abcc6c. This
is due to a genome duplication event that occurred during
evolution of this species, resulting in a large number of ZF
genes to be present in 2 or more copies, which may possibly
complicate function analysis [68, 69]. However, in some
genes, the ancestral gene function was partitioned between
the descendant genes, making it possible to study several
aspects of the ancestral (and sole human) gene functions
separately [70].
Li et al. characterized a morpholino knockdown ZF
model, targeting the abcc6a isoform, which developed peri-
cardial edema, a curved tail, and stunted growth, but no
ectopic mineralization, possibly due to the early demise of
the morphants. Indeed, all embryos died within the first
week of life, suggesting that in ZF abcc6a is an essential
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Table 2: Mineralization phenotypes of PXE-related murine strains (based on [60]).
Strain Phenotype
129S1/SvImJ Fibroosseous bone lesions
∗
Vibrissae mineralization
C3H/HeJ Epicardial fibrosis and mineralizationFibroosseous bone lesions∗
DBA/2J
Epicardial fibrosis and mineralization
Fibroosseous bone lesions∗
Arterial mineralization
KK/HIJ
Systemic mineralization (lung, retina)
Epicardial fibrosis and mineralization
Fibroosseous bone lesions∗
Arterial mineralization
Vibrissae mineralization
Hyperplasia (most common in pancreatic islets) [24009271]
Abcc6−/− (targeted ablation)
Spontaneous calcification of EFs (mainly in arteries, the renal cortex, and the
capsule surrounding the sinuses of the vibrissae)
Normal plasma mineral levels
Mineralization of dermal EFs and collagen
Lower plasma HDL cholesterol
Increased plasma creatinine
Abcc6−/− (deletion of NBF1)
Spontaneous calcification of EFs (mainly in arteries, the renal cortex, and the
capsule surrounding the sinuses of the vibrissae)
Normal plasma mineral levels
DCC or Dyscalc Myocardial calcificationAbsence of vascular and vibrissa calcification
∗This lesion was also found in strains without PXE-like mineralization and was not linked to EF calcification. Probably this lesion is thus not associated with
PXE or Abcc6 was a strong modifier gene in KK/HIJ mice when mutated [60]. The other described lesions, apart from hyperplasia in the KK/HIJ mouse, can
be linked to PXE. NBF1: nucleotide-binding fold 1.
protein for normal development [67]. Besides this morphant,
also a permanent mutant ZF has been studied which shows
extensive hypermineralization of the skeleton [71].
The availability of a ZF model for PXE opens novel
avenues for functional evaluation of ABCC6 mutations (see
Molecular Analysis Tools) and for the screening of potential
therapeutic compounds [66, 72, 73].
Compound screening, that is, a screening to assess the
physiological and possible therapeutic effects of chemical
compounds by adding them to the water in the ZF tank, can
be done using different assays and via a targeted or a blind
approach. The latter is done via simultaneous testing of mul-
tiple compounds from a compound library. Both approaches
are complementary, as a targeted approach often is unsuccess-
ful due to the development of compounds with bad absorp-
tion, distribution, metabolization, excretion, and toxicology
(ADMET) properties [65]. Due to the advantages inherent to
ZF, compound screening in ZF has become easier and faster
than it was using other animal models, such as the mouse
and even Drosophila [65, 72, 73]. Even though the mouse
model is still considered more relevant for humans than ZF,
it is much more difficult and expensive to manipulate mouse
embryos, which need a uterine environment to develop
properly and are much more expensive to produce in large
numbers compared to ZF embryos [65, 72].
Currently, no blind compound screenings have been
performed for Abcc6, but a targeted approach with 4-phenyl-
butyrate (4-PBA) was successfully applied to rescue the
phenotype caused by specific missense mutations. 4-PBA is
a chemical chaperone drug that has already been successfully
used in cystic fibrosis to restore the plasma membrane local-
ization of CFTR (cystic fibrosis transmembrane conductance
regulator, OMIM∗602421) in the presence of the frequent
Δ508 mutation. A major advantage of 4-PBA is that it is
already approved by the US Food and Drug Administration
(FDA) for other indications (urea cycle disorders and tha-
lassemia) [21, 49–51]. For 7 abcc6 missense mutations which
led to mislocalization of the abcc6 transporter but with intact
transport activity, 4-PBA could restore the plasmamembrane
localization in 4, confirming in vivo what was previously
shown in vitro in mouse liver tissues [20]. This suggests that
an allele-specific treatment may be interesting in PXE (and
GACI). Further, in the permanent mutant PXE ZF model
treatment with vitamin K supplementation was evaluated
[71]. Interestingly, such treatment was able to rescue the
phenotype. This is in contradiction with previous experi-
ments in Abcc6−/− mice, in which vitamin K did not have
any effect on the mineralization phenotype [74–76]. These
results suggest that there are species-dependent peculiarities
with regard to ABCC6 and lead to speculating on the
reliability of either the ZF or mouse experimental results
8 BioMed Research International
for the potential treatment of PXE patients with vitamin K
supplementation.
3.3. In Vitro Models. Besides animal models, several in vitro
cell models are being used to study the physiological roles
of the ABCC6 transporter and for evaluating therapeutic
interventions. The most reliable cell models remain those
derived from patient tissues of which skin fibroblasts remain
the most frequently used. For many of the tissues of interest
to study the physiological properties of ABCC6, such as the
liver or kidney, human cell samples are rare and other in vitro
model systems are therefore applied. Among these, the most
frequently used are Sf9, MDCKII, HepG2, and HEK293 cells.
3.3.1. Patient-Derived Cell Systems. The patient-derived cells,
most frequently used to study the function and underlying
etiopathogenetic mechanisms of ABCC6, are dermal fibro-
blasts. In the 70s and 80s multiple studies showed that serum
from cultured PXE fibroblasts had a higher protease activity
than serum from controls [77, 78]. Later, Le Saux et al. found
that human fibroblasts and smooth muscle cells form EF
aggregates when maintained in serum from PXE patients,
suggesting the presence of disease-specific components in
PXE serum [79]. Furthermore, abnormal cell-cell and cell-
matrix interactions and amodified proliferative capacity were
identified in fibroblasts from PXE patients [79]. This fed
the hypothesis of PXE as a metabolic disease, in which the
defective ABCC6 transporter is unable to secrete one or
more substrates into the serum. More recently, knowledge
on mediators involved in ABCC6-related mineralization was
derived from dermal PXE fibroblasts, using metabolomics
and proteomics technologies (see below) and expression
arrays [46, 80, 81].
Furthermore, MMP2 was found to be upregulated in
PXE fibroblasts; MGP was found to be highly uncarboxy-
lated and thus inactive to counteract soft tissue miner-
alization; multiple pro-osteogenic pathways, that is, the
BMP2-Smad-RUNX2 (BMP2: bone morphogenetic protein
2, OMIM∗112261; Smad: mothers against decapentaplegic,
Drosophila, homolog of, OMIM∗601366; RUNX2: runt-
related transcription factor 2, OMIM∗60021) and TGF𝛽2-
Smad2/3 WNT pathways (TGF𝛽2: transforming growth
factor, 𝛽2, OMIM∗190220) and the MSX2-canonical WNT
(MSX2: muscle segment homeobox, Drosophila, homolog
of, 2, OMIM∗123101; canonical WNT: wingless-type MMTV
integration site family, OMIM∗164820), were found to be
upregulated in fibroblasts from PXE patients and were
associated with an abnormal cholesterol and lipoprotein
metabolism, reinforcing the higher cardiovascular risk found
in PXE patients [15, 25, 81, 82]. Very recently, Dabisch-
Ruthe et al. identified a strong reduction of the inorganic
pyrophosphate (PPi) levels in dermal PXE fibroblasts leading
to ectopic mineralization. This could be reduced by PPi
addition, confirmingwhat had been shown earlier in primary
hepatocytes and in vivo liver perfusion experiments [24, 83].
Fibroblasts have also been used to investigate the possible
substrates of ABCC6, via immunohistochemistry assays and
qPCR experiments and via fluorescence assays in the absence
and presence of inhibitors/competitors of ABCC6; however,
these experiments have thus far mostly been unsuccessful
[84, 85]. Besides the metabolic hypothesis, fibroblast studies
have been at the basis of the cellular hypothesis of PXE, with
the presence of an increased oxidative stress and a higher
susceptibility to procalcifying stimuli [86, 87]. Furthermore,
abnormal cell-cell and cell-matrix interactions and a modi-
fied proliferative capacity were identified in fibroblasts from
PXE patients [88–91].
3.3.2. Non-Patient-Derived (Non)humanCell Lines. Sf9 insect
cells are a clonal isolate of Spodoptera frugiperda Sf21 cells,
which were originally established from ovarian cells [92].
This cell line is commonly used for recombinant protein and
after expressing human kidney ABCC6 cDNA on isolated
membranes of Sf9 cells using a viral vector (such as a bac-
ulovirus vector or pBluescript SK vector) it was shown
that human ABCC6 has a high capacity drug-stimulated
ATPase activity and that it actively transports leukotriene
C(4) and N-ethylmaleimide S-glutathione (NEM-GS) [19,
93]. This transport capacity was inhibited by organic anions
(probenecid, benzbromarone, and indomethacin) and 3PXE-
causing missense mutants, although a normal MgATP bind-
ing was still possible, indicating that human ABCC6 is a
primary active transporter for organic anions [19]. However,
the transport rate of these in vitro substrates was low and
it was deemed that these could not be the physiological
compounds transported by ABCC6 [19]. More recently, the
observation of low serum vitaminK levels in PXE patients led
to the use of this Sf9cell model to show that ABCC6 did not
transport the glutathione conjugate of vitamin K3 (VK3GS)
[94].
In subsequent studies, experiments in Sf9 cells were often
complemented with MDCKII cells (polarized Madin-Darby
canine kidney II renal epithelial cells), particularly as in the
latter the subcellular localization of ABCC6 at the basolateral
cell membrane and N-glycosylation sites were discovered
[95]. Further refinement of expression studies, using not only
the complete human ABCC6 but also truncated forms (with,
e.g., only the TMD0 or the L0), revealed that the TMD0
region is not required for ABCC6 transport function (forma-
tion of a transition-state intermediate or nucleotide trapping
and leukotriene C4 and N-ethylmaleimide glutathione trans-
port) nor for its proper routing to the plasmamembrane [96].
Similarly, it was noted that glycine residues in the ABCmotifs
and catalytic domain of ABCC6 were of particular impor-
tance for its transport function as mutations affecting such
conserved glycine residues induced a decrease in ATPase
activity, though the ATP binding properties were preserved
[97]. Moreover, nucleotide trapping was still possible in these
mutants although itwas inhibited byABCC6-substrate drugs,
which was possibly due to a miscommunication between the
NBFs and the catalytic domains (within the ABC motifs) in
ABCC6 [97].
MDCKII cells have also been successfully used to evaluate
the therapeutic potential of 4-PBA to overcome incorrect
plasma membrane trafficking due to ABCC6missense muta-
tions [20].
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As an alternative kidney cell model, HEK293 cells
(Human Embryonic Kidney 293 cells) are used. Jansen et al.
showed thatmedium from theseHEK293 cells in which rat or
human ABCC6 was overexpressed inhibited mineralization
in vitro in the chondrogenic cell line ATDC5 (derived from
teratocarcinoma AT805), whereas medium from HEK293
control cells did not.This suggests that in serumderived from
PXE patients promineralizing factors are present inducing
this in vitromineralization, as Le Saux et al. concluded before
on fibroblasts [47, 79].
Besides kidney cells, the expression profile of ABCC6 also
led to the use of HEPG2 cells as an in vitro model system to
study polarized human hepatocytes, particularly because of
the paucity of patient-derived tissue from this organ. ABCC6
knockdown in HepG2 cells to study mineralization revealed
that the promineralizing factor TNAP was upregulated and
antimineralizing factors NT5E (CD73), SPP1, and fetuin-A
were downregulated [26].
3.4. Metabolomics. Metabolomics is the study of metabo-
lites, which are involved in biological processes in cells,
tissues, and organisms. Several methodological approaches
can be used, such as capillary electrophoresis and High
Performance Liquid Chromatography (HPLC). For ABCC6,
mostmetabolic profilingwas done using gas chromatography
with mass spectrometry. Untargeted metabolic profiling via
mass spectrometry comparing human dermal fibroblasts
from PXE patients with healthy controls showed substan-
tial alterations in levels of fatty acids, leucine dipeptides,
proline oligopeptides, the polypeptide Ac-Ser-Asp-Lys-Pro-
OH (AcSDKP), and of pantothenate in cell lysates from PXE
patients. These alterations are linked to a.o. cytoskeleton and
ECM reorganization, atherogenesis, and angiogenesis, all of
which can be localized in the extracellular compartment.
Moreover, decreased levels of pantothenate are associated
with an increased oxidative stress which, together with ECM
remodeling, is a hallmark of the PXE pathogenesis [48].
Jansen et al. also used an untargeted metabolic approach via
mass spectrometry, showing an accumulation of nucleoside
triphosphates in the supernatant of ABCC6-overexpressing
HEK293 cells. Unfortunately, LC-MS experiments on plasma
of Abcc6−/− and control mice did not confirm the difference
between these metabolites. Although ATP is not directly
transported by ABCC6, the transport is probably ABCC6-
dependent. Furthermore, in this serum an increase in the
extracellular PPi levels, a potent antimineralizing agent, was
found. In vitro and in vivomodels showed that PPi concentra-
tion was significantly lower when ABCC6 was deficient, thus
leading to ectopic mineralization [47].
3.5. Proteomics. Aproteomics approach studies the structure,
function, and interactions of proteins produced by genes
in a particular organism, tissue, or cell. This method was
applied by Boraldi et al. who compared protein profiles in
dermal fibroblasts between PXE patients and controls, using
2D gel electrophoresis coupled to mass spectrometry. They
identified a decreased protein disulfide isomerase (PDI) level,
a protein that is localized in the endoplasmic reticulum (ER)
and that is important for proper functioning of the vitamin
K cycle. A decrease in PDI leads to a deficient function of
vitamin K-dependent processes such as 𝛾-carboxylation,
which is an essential step for the activation of certain proteins,
for example, ofmatrixGla protein (matrix 𝛾-carboxyglutamic
acid or MGP, OMIM∗154870). Loss of 𝛾-carboxylation of
MGP, which is specifically linked to EFs, leads to a loss of
inhibition of EF mineralization. Furthermore, an increase
in calumenin levels, having an inhibitory effect on 𝛾-
carboxylase, was seen in the ER. Apart from perturbation of
the vitamin K cycle, a significant upregulation of superox-
ide anions (O2
−) production and mitochondrial superoxide
dismutase (Mn-SOD) activity as well as an increase in the
extracellular SOD (EC-SOD) concentration was found in
PXE fibroblasts compared to controls, which can be linked to
increased oxidative stress. Moreover, downregulation of the
chaperone protein heat shock protein 60 (Hsp60 or HSPD1,
OMIM∗118190), which is required for the correct folding
of polypeptides under normal and stress conditions, was
identified. This indicates that PXE fibroblasts may be less
reactive to tissue injury [46]. The differentially expressed
proteins can be targets for validation and efficacy testing
of future therapies in PXE fibroblasts (targeted compound
screening; see above) [46]. It must be noted that thus far
most of the findings from the metabolomics and proteomics
studies, such as the involvement of oxidative stress and MGP
in theABCC6-related biologicalmechanisms,mostly validate
data obtained from previous in vitro and in vivo experiments.
This is not surprising, since the data obtained through these
untargeted experimental approaches was analyzed mainly in
a hypothesis-driven, targeted manner.
3.6. Homology Modeling and Molecular Docking. Further
insights into the potential substrates of ABCC6 were gained
through computational models, such as homology modeling
and molecular docking. Homology modeling is the predic-
tion of the structure of a protein based on the structure of a
homologous protein (e.g., from the same (super)family). The
more the amino acids are conserved between both proteins,
the better the prediction of the structure is. Subsequently,
molecular docking is an in silico technique, used to predict the
best orientation of a putative substrate in the binding pocket
of a protein in order to form a stable complex [52], in this way
helping to find the substrate(s) of a certain protein.
The first ABCC6 homologymodel was designed by Fu¨lop
et al. in 2009, which enabled defining clustering of disease-
causing mutations to complex domain-domain interfaces in
the ABCC6 transporter. These interfaces include the trans-
mission interface, involving 4 intracellular loops and the 2
ABC domains, and the ABC-ABC interacting surfaces. The
mutation prevalence in these regions was 2,75- and 3,53-
fold more frequent than the average mutational rates along
the ABCC6 transporter. Furthermore, interactions of the
mutations within these interfaces were identified [53]. This
3D model was further refined by Hosen et al. and led to
better insights into the binding of reported in vitro substrates
to the ABCC6 protein, by identifying two substrate binding
pockets. Blind docking experiments in the open and closed
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conformation of the protein have enabled generating a list
of possible substrates from the HumanMetabolome database
[54].These in silicomodeling techniques can contribute to the
discovery of the putative ABCC6 substrate(s), which can then
be further tested in vitro and in vivo [54].
3.7. Towards an Integration of Experimental Data. Following
the wide variety of approaches used to gain insights into the
ABCC6 transporter and the large number of observations
related to this transporter, to date, one of the main chal-
lenges remains to integrate all these observations into a
(patho)physiological model of ABCC6. An interesting initia-
tive in this respect is the Clinical and Functional Translation
of CFTR (CFTR2) project, which deals with a different ABC
transporter, CFTR or ABCC7, causing cystic fibrosis (Castel-
lani and CFTR2 team, 2013). The CFTR2 project aims to
integrate clinical,molecular, and functional data on theCFTR
gene and its encoded protein in a single database, curated
by a data manager. Such an initiative stands as an example
for a novel cloud-based data management system which is
being implemented in Ghent, Belgium, as a prerequisite for
a European and international initiative to have a complete
overview of research observations on ABCC6 and thus move
forward efficiently in understanding this protein.
4. Relevance of ABCC6 for Complex and Rare
Disorders and Disease Risk Factors
4.1. Kidney Disease
4.1.1. Chronic Kidney Disease. Though PXE patients them-
selves only rarely present nephrological problems, except for
the occasional observation of ectopic calcification foci in the
kidney parenchyma, the vascular tunica media calcifications
in PXE show a striking resemblance with vascular disease
seen in chronic kidney disease (CKD) patients: fragmen-
tation of EFs is present in the aortic wall of CKD mice
and fragmentation of medial EFs has been described in
CKD patients [98–100]. This arterial disease contributes
more to the high prevalence of cardiovascular morbidity and
mortality than does the development of end-stage kidney
failure [101]. In the dialysis population, mortality risk is most
marked in the younger age group (25–34 years old), where
the cardiovascular death rate is up to 500-fold greater than in
the age-matched control group [30]. Several mediators have
been discovered which are involved in CKD-related vascular
disease, promoting soft tissuemineralization and accelerating
arterial calcification. These include systemic inflammation,
altered calcium and phosphate homeostasis, hypertension,
and a deficiency of endogenous calcification inhibitors such
as Klotho, MGP, PPi, and fetuin-A [30, 102]. However, com-
mon mechanisms underlying these pathophysiological aber-
rations have not been determined.
Because of the histological resemblance, Lau et al. studied
the potential involvement of the Abcc6 transporter in CKD
rats and mice and found a significantly decreased level of
Abcc6 protein in their liver and kidney tissues [30]. As the
Abcc6 mRNA levels were normal, this was likely due to an
as yet unidentified posttranscriptional or posttranslational
mechanism. However, if extrapolated to the human situation,
it suggests that an acquired ABCC6 deficiency contributes
to accelerated arterial calcification in CKD patients which
may explain the highly prevalentmedial calcification inCKD,
even in the absence of traditional atherosclerotic risk factors,
for example, in pediatric dialysis patients. Indeed, it has
been demonstrated inmice with anApoE−/− background that
an Abcc6 deletion results in medial calcification within the
vessel wall without calcification or enlargement of existing
atherosclerotic lesions [31]. These findings are of interest
because in PXE a disturbance of MGP, PPi, and fetuin-A
has also been shown and related to the deficient ABCC6
transporter [24, 27].The involvement of ABCC6 thus gives an
explanation for at least some of the pathophysiological obser-
vations previously done in CKD. Furthermore, it confirms
that the function of the ABCC6 transporter is not restricted
to a multisystem calcification disease such as PXE but also
contributes to vascular disease without causing any of the
other phenotypic features for which it is renowned. Finally,
these findings may also have therapeutic consequences.
Indeed, overexpression of fetuin-A inAbcc6−/−mice has been
shown to attenuate soft tissue mineralization [63]. Moreover,
recently, the use of bisphosphonates, that is, nonhydrolyzable
PPi analogs, has been suggested as a potential treatment for
ABCC6-related mineralization, to counteract PPi deficiency
[47].
4.1.2. Nephrocalcinosis. A second renal phenotype in which
ABCC6 was shown to play a role is nephrocalcinosis. It
is characterized by aberrant deposition of calcium in the
kidney parenchyma and tubules and can be associated with
a number of systemic and renal metabolic diseases, including
acute phosphate nephropathy, primary hyperparathyroidism,
and distal renal tubular acidosis [103]. The aberrant calcium
deposition may be asymptomatic but can eventually lead
to progressive renal failure and end-stage renal disease. It
has been suggested that nephrocalcinosis could be consid-
ered a passive phenomenon resulting from deposition of
a supersaturated phosphate product associated with tissue
remodeling and ultimately leading to the loss of functional
renal parenchyma [104]. However, the mechanisms underly-
ing many of the pathological conditions resulting in ectopic
calcium deposition in the kidney remain to be explored.
An association of PXE with nephrocalcinosis was
described in a few cases [32]. Though these may have been
fortuitous, Li et al. further examined the presence of nephro-
calcinosis in two animal models of ectopic mineralization,
respectively, the Abcc−/− (via targeted ablation) and Enpp1asj
mutant mouse, an animal model for generalized arterial
calcification of infancy, both characterized by multisystem
deposition of mineral crystals [57, 105, 106]. These mice
develop nephrocalcinosis only at a later age when fed with
a normal diet. Treated with a calcification-accelerating diet
(containing decreased amounts of magnesium and increased
phosphate), these animals develop extensive mineralization
in the kidney interstitium, primarily affecting the medullary
tubules as well as the arcuate and renal arteries. Interestingly,
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the heterozygous mutant mice did not develop nephrocal-
cinosis, while in the compound heterozygous mice mineral
deposits in the kidneys were shown to consist of calcium
and phosphate, suggesting the presence of hydroxyapatite
crystals, which is similar to human nephrocalcinosis [106].
This is the first evidence of a synergistic effect of two defects
in mineralization homeostasis modulating soft tissue calcifi-
cation in a common disease such as nephrocalcinosis.
4.2. Cardiovascular Disease
4.2.1. Coronary Heart Disease. Coronary heart disease
(CHD) is a major cause of death and disability in our society,
causing approximately 450,000 deaths/year in the United
States only. Besides environmental factors, there is evidence
for a strong genetic predisposition with currently over 50
genetic risk factors identified [107]. Most of these are related
to dyslipidemia or have an as yet to be elucidatedmechanism.
Though in PXE patients CHD is less frequent compared
to peripheral artery disease, studies have been conducted
to evaluate whether ABCC6 variants may be susceptibility
alleles for CHD beyond PXE [9]. Some studies have shown
that the frequent R1141X mutation is risk factor for CHD
among Caucasians, even in heterozygous state [9, 33, 108].
However, others were not able to show this association,
which is in analogy with the absence of a genotype-pheno-
type correlation between ABCC6 mutations and the PXE
phenotype [109]. Thus far no other studies have been done
looking at a possible association between the whole ABCC6
mutation spectrum and CHD instead of focusing merely on
a single mutation. A need for such a more global evaluation
seems highly relevant as several observations in Abcc6-
deficient mice also point towards a causal relationship with
CHD.
Mungrue et al. found an increased infarct size and apop-
tosis in a mouse cardiac ischemia-reperfusion model based
on a naturally occurring Abcc6 deficiency, suggesting a role
for Abcc6 in cardioprotection as a novel modulator of
cardiac myocyte survival after ischemia-reperfusion [110]. It
was shown that the BMP-responsive transcription factors
pSmad1/5/8 were upregulated in the cardiac tissue of these
Abcc6−/−mice together with an increased propensity to apop-
tosis. Both are very similar to what is found in PXE patients
and suggest that BMP signaling and apoptosis are end results
of ABCC6 deficiency [15].
Moreover, the level of hepatic Abcc6 expression also
determined the severity of postinjury calcification, thusmak-
ing this an important factor in determining myocardial
dystrophic calcification [111]. Although less frequent than
vascular calcification, myocardial dystrophic calcification
occurs in long-term survivors of myocardial infarction with
an occasionally extremely severe presentation [112]. These
observations should not come as a surprise, given that a splice
site Abcc6 allele was previously found to be the cause of a
cardiac phenotype in mice coined dystrophic cardiac cal-
cification or DCC in which myocardial calcification is a
hallmark [29]. The results of the experiments support the
notion that the substrate(s) of ABCC6 may have a wider
therapeutic value, stretching to myocardial infarction. These
results also define a novel mechanism of adverse outcome
after cardiac injury and again support the usefulness of a
broader examination of ABCC6 variants (both mutations
and SNPs) in cardiovascular disease. Similarly, Rau et al.
applied genome-wide association studies (GWAS) in mice
after 𝛽-adrenergic stimulation and detected 7 significant loci
affecting cardiac hypertrophy, fibrosis, and heart failure, one
of which harbored the Abcc6 gene. Functional evaluation
demonstrated that a splice site mutation in ABCC6 strongly
promoted stress-induced cardiac fibrosis, thus corroborating
ABCC6 as an unrecognized and novel player in the develop-
ment of cardiac fibrosis and acquired cardiomyopathy [34].
4.2.2. Dyslipidemia. One of the most important cardiovascu-
lar risk factors is dyslipidemia. Population studies have shown
that a strong inverse relationship exists between plasma high-
density lipoprotein cholesterol (HDL-C) concentrations and
CHD risk [113–116]. Indeed, a low level of HDL-C is the
most common plasma lipid abnormality observed in men
with established CHD [117]. In addition to environmental
factors, strong evidence exists for the role of genetics in the
determination of HDL-C levels with heritability estimates in
the range of 40–60% [118].
Since several ABC transporters are involved in lipid
homeostasis, a role for ABCC6 in the lipoproteinmetabolism
was not surprising and this was corroborated by several
studies. Allelic variants in the ABCC6 gene (rs150468 and
rs212077) were found to be associated with susceptibility to
low HDL-C and CHD [119]. A haplotype analysis of these
two SNPs demonstrated that the haplotype with the AC
alleles (frequency of 81% in studied population) had a 56%
increased risk to develop CHD/low HDL-C compared to the
CG haplotype (frequency of 16%) [119].
Cross-sectional studies involving relatively large numbers
of PXE patients indicated a higher than expected preva-
lence of hypertriglyceridemia and depressed plasma HDL
cholesterol [120]. PXE patients with moderately severe type
IV hyperlipoproteinemia were screened and it was shown
that ABCC6 p.(R1164X) nonsense mutation and the ABCC6
p.(R1268Q) SNP are associated with dyslipidemia, character-
ized by high plasma triglyceride and low HDL cholesterol
[35, 36].
Very similar findings were seen in experiments in
Abcc6−/− mice showing a 25% reduction in plasma HDL-C,
confirming the potential role of ABCC6 in lipid homeostasis
[28]. The possible relevance of these lipid abnormalities for
soft tissue mineralization was demonstrated by Guo et al.,
who found that atorvastatin counteracts soft tissue miner-
alization in Abcc6-deficient mice [37]. Very recently, Kuzaj
et al. documented increased ABCC6 transcription levels as
well as an increased cholesterol biosynthesis in lipoprotein-
deficient serum. Furthermore, the serum also contained
elevated PCSK9 (proprotein convertase, subtilisin/kexin-
type 9, OMIM∗607786) levels, which cause a decrease
of (extra)hepatic levels of LDL-C (low-density lipoprotein
cholesterol) receptors and an increase in LDL plasma con-
centration. In PXE fibroblasts a reduction of ApoE mRNA
12 BioMed Research International
expression was identified [81]. These findings further stress
the importance of ABCC6 variants, both gain- and loss-of-
function, in the cardiovascular disease risk of the general
population.
4.2.3. Vascular Aneurysms. An abdominal aortic aneurysm
(AAA) is a complex multifactorial disease with a prevalence
of 1–6% in industrialized countries, the etiology of which
is incompletely understood. This disease is characterized by
arterial wall dilatation accompanied by the degradation of
elastin and collagen fibers. The most severe complication
of this disorder is a rupture of the weakened vessel wall
leading to significant mortality andmorbidity.While in some
individuals there is a clear genetic predisposition, other cases
of AAA seem to arise spontaneously [121].
Contrary to other connective tissue diseases such as
Marfan syndrome or the vascular type of the Ehlers-Danlos
syndrome, in PXE patients aneurysms are sparse if not
anecdotic [122]. Aortocoronary aneurysms have also been
reported but seem not to be specific to PXE since they have
also been reported in other PXE-like phenotypes such as
in the PXE phenocopy associated with beta-thalassemia [38,
123].
To date, only 1 study has been conducted, which inves-
tigates the potential association of ABCC6 mutations and
AAA. Mutations were found in only a small minority of non-
PXE patients (5/133) with AAAs [124]; however, this was not
statistically different from healthy controls. Further research
would be appropriate before drawing a definite conclusion
not to consider ABCC6 as a genetic risk factor for AAA.
4.3. Ophthalmological Disease
4.3.1. Age-Related Macular Degeneration. In the European
and North American population age-related macular degen-
eration (AMD) is a main cause of irreversible, central blind-
ness in patients over 50 years of age. It is a common multi-
factorial disorder, causing a progressive deterioration of
macular function, which is responsible for central vision
[125–127]. In an advanced stage, the disease is classified into
2 forms: a dry, nonexudative form and a wet or exudative
form. The wet form, being responsible for 90% of the AMD-
related vision loss, is characterized by subretinal neovas-
cularization and hemorrhage, which are also hallmarks of
PXE [11, 12, 126]. As a prototype multifactorial disease, the
pathophysiologic factors in AMD include not only changes
in Bruch’s membrane but also oxidative stress [128]. In mul-
tifactorial diseases, it is difficult to separate primary effects
from secondary effects that eventually lead to functional loss.
For instance, choroidal alterations could occur, secondary to
changes in Bruch’s membrane. To investigate such specific
components in AMD pathology a detailed investigation
of human monogenic disease with clearly defined changes
mimicking specific components is very useful.
PXE is a good candidate for studying the impact of altered
Bruch’s membrane as the primary pathologic alteration in
eyes of patients with PXE appears to be a thickening and
calcification of thismembrane [12, 129]. In later disease stages,
the disease shares various phenotypic similarities with AMD,
including a high risk for developing choroidal neovascular-
ization or chorioretinal atrophy of the macular region [12]. A
significant reduction of mean subfoveal choroidal thickness
was found in the eyes of PXE patients. PXE eyes without
CNV or chorioretinal atrophy showed the least reduction
of choroidal thickness, while it was most pronounced in
PXE eyes with chorioretinal atrophy. The results indicate
that changes of Bruch’s membrane can be associated with
choroidal alterations, which are most pronounced in the
presence of advanced disease. A role for Bruch’s membrane
in choroidal homeostasis may reflect a possible contribution
of Bruch’s membrane alterations to CNV and geographic
atrophy development in age-related macular degeneration
[12, 130].
4.4. Cerebrovascular Disease
4.4.1. Ischemic Stroke. Stroke is amultifactorial and polygenic
disease, which has a monogenic basis in only a small per-
centage of cases. In the general population, the incidence of
ischemic stroke under 65 years is 229/100,000/year [131–133].
There is increasing evidence of an important genetic compo-
nent in the etiology of stroke [134]. Especially in cryptogenic
stroke, where no clear cerebrovascular risk factors or triggers
can be found to explain the acute event, the identification of
one or more genetic variants (either as a monogenic cause or
as a susceptibility factor) can have important implications for
therapeutic management and genetic counseling.
A large number of single-gene disorders, including PXE,
have been described to be associated with stroke. In PXE,
ischemic stroke is caused by large artery disease or less
frequently by small-vessel occlusive disease [9]. Moreover,
hypertension, which is very common in patients with PXE,
favors cerebrovascular episodes [135, 136].
The role of heterozygous ABCC6 variants in cryptogenic
ischemic stroke has been investigated in a pilot study in our
group. The frequency of ABCC6 mutations—not limited to
the frequent p.(R1141X) mutation—was found to be much
more frequent in the stroke cohort compared to controls,
with an odds ratio of 5. This would imply that heterozygous
ABCC6 mutations are an important risk factor for the
development of ischemic stroke, whichwould have important
implications for the counseling and management of PXE and
cryptogenic stroke families. However, Ko¨blo¨s et al. found no
association between carriers of the p.(R1141X) mutation and
stroke, indicating that further research is needed before a
conclusion can bemade [33]. Similar toCHD, it is worthwhile
to evaluate the completeABCC6mutation spectrum to clarify
these conflicting results.
A possible role of ABCC6 in the central nervous system
was recently enforced by Wakabayashi et al. who, using flow
cytometry, showed the presence of a side population (SP) of
endothelial cells in brain vessels, capable of exteriorizing the
Hoechst 33342 dye in C57BL/6 and C57BL/6-Tg, a variant
of the former strain containing enhanced GFP cDNA that
makes all the tissues (except hair and erythrocytes) appear
green under excitation light, mouse models. Similar SP cells
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have already been shown to cause resistance in cancer cells
by enhancing the efflux of chemotherapeutics. This feature
is linked to a high ABC transporter activity, among which
the ABCC6 transporter seems to be of importance, as was
shown by its high mRNA levels in the murine brain tissues.
Due to their efflux capacity, these SP cells seem to play an
important role in brain homeostasis, by contributing to the
brain’s barrier functions (i.e., the blood-brain barrier) and
prevention of cytotoxicity to the brain parenchyma [137].This
suggests that an impairment of the ABCC6 transporter may
cause dysfunction of the blood-brain barrier and puts the
focus on the role of ABCC6 in the cerebral vasculature.
4.4.2. Spontaneous Carotid Artery Dissections (sCAD). In
a similar way, the frequency of ABCC6 variants has been
studied in patients with spontaneous carotid artery dis-
sections (sCAD). sCAD represents an important cause of
stroke among young and middle aged patients and can occur
without relevant trauma in otherwise healthy individuals
without known risk factors [138]. Although the clinical and
diagnostic criteria for sCAD are well established, the patho-
genesis is still a matter of speculation. In some patients with
sCAD the reticular dermis has a similar, although less severe,
morphology to heterozygous relatives of PXE patients with
fragmented, cribriform, and mineralized collagen bundles
and EFs [139]. However, Morcher et al. were not able to find
an association between ABCC6 variants and sCAD patients
with pronounced electron microscopic alterations in the
dermal connective tissues [140]. Though it was concluded
that ABCC6 is not a candidate gene for sCAD, we should be
careful to draw definite conclusions based on a single study.
4.5. Familial Mediterranean Fever. Familial Mediterranean
fever (FMF) is an autosomal recessive disorder caused
by mutations in the MEFV (familial Mediterranean fever
gene, OMIM∗608107) gene and is characterized by recurrent
inflammatory attacks, mainly affecting ethnic groups origi-
nating from countries around the Mediterranean Sea. FMF
shows amarked variability in clinical expression between and
within families [141, 142]. Amyloidosis, one of the severe com-
plications of FMF, was relatively frequent before the advent of
colchicine as a therapy. The risk of amyloidosis depends on
contributing factors, such as ethnicity, nature of the MEFV
mutation, the SAA1 (serum amyloidA1,OMIM∗104750) gene
haplotype, and environmental factors [143, 144]. However,
these factors do not account for the total contribution to
amyloidosis susceptibility. A patient suffering from both
FMF and PXE was found to be homozygous for both the
p.(Met694Ile) mutation in MEFV and p.(Gly1042Ser) in
ABCC6 [145, 146]. As this patient developed severe amyloi-
dosis despite appropriate colchicine treatment, the possibility
that ABCC6 deficiency contributed to the severity of FMF
was raised. Two nonexclusive pathogenic explanations have
been proposed: increased amyloid deposition in target tissues
and/or decrease in colchicine activity [145]. Though thus far
no validation studies have been performed, the identification
of ABCC6 variants would be important in improving the
accuracy of amyloidosis risk prediction in patients and in
extending our understanding of the pathophysiology of FMF.
4.6. Beta-Thalassemia. Beta-thalassemia is a mostly autoso-
mal recessive disorder caused bymutations in the beta-globin
gene, which leads to diminution of the protein concentration.
The disease has a highly variable phenotype and is relatively
frequent in the Mediterranean population, the Middle East,
India, and Southeast Asia. Although beta-thalassemia is not
caused by ABCC6 mutations [39–41], patients may develop
an ectopicmineralization phenotype, identical to PXE, which
is thus considered a PXE phenocopy [38, 42–44]. Although
in humans no apparent link with ABCC6 (dys)function
has been demonstrated, there is some evidence in murine
models that Abcc6 is involved in the occurrence of this
phenocopy. Indeed, perturbation of Abcc6 function was
found in a 𝛽-thalassemia mouse model (𝐻𝑏𝑏𝑡ℎ3/+), showing
a progressive liver-specific downregulation of Abcc6 gene
expression.This downregulation is due to the absence of NF-
E2, a transcription factor from the Abcc6 promotor, which
is also an important transcription factor involved in the
regulation of expression of several hemoglobin-related genes
[41, 45]. It should however be noted that these mice did not
develop spontaneous calcification, possibly due to the genetic
background of these mice (DCC-resistant C57BL/6J) or due
to the fact that the Abcc6 decrease only occurred late in life
[40, 41].
5. Conclusions
The example of ABCC6 shows that genes that are initially dis-
covered as the cause of orphan diseases can have widespread
effects with implications for a wide range of common,
often complex, diseases. This expands the knowledge on the
genetic etiology of these diseases and can have beneficial
effects on the diagnosis, follow-up, and management as
well as treatment of patients suffering from these diseases.
At the same time, ABCC6 exemplifies the complexity of
the biological systems that underlie these diseases and the
pleiotropy of approaches, which is necessary to unravel
the associated (patho)physiology. ABCC6-related research
demonstrates the feasibility of translating findings in animal
studies to humans; at the same time, it emphasizes the
continuous need for thorough and comprehensive studies, for
example, studies which investigate not only a single ABCC6
mutation but the whole mutation spectrum to identify risk
alleles for CHD and stroke, certainly as many indications
exist for the relevance of ABCC6 in these disorders, as well
as replication studies. The main challenge for the future is
the so-called multilayered data integration. Specifically for
ABCC6, we have started with the development of a cloud-
based system which is able to document and integrate the
clinical, molecular, histological, and biochemical data of
individual patients together with their data obtained from
proteomics, metabolomics, and expression arrays. As this
integrative system (under the control of a data manager) will
be open to other research groups, it will be a valuable asset to
14 BioMed Research International
move forward in understanding the role of ABCC6 in human
disease.
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